Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H B Richards

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Lupus|October 27, 2001
Titration emulation: a computer-assisted technique that simplifies the quantification of anti-dsDNA antibodies using the Crithidia luciliae assayM Satoh, K M Behney, A Mizutani, et al.
Scandinavian Journal of Rheumatology|February 21, 2018
Secukinumab after anti-tumour necrosis factor-α therapy: a phase III study in active rheumatoid arthritisE Dokoupilová, J Aelion, T Takeuchi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 6, 2000
Fas and Fas ligand mutations inhibit autoantibody production in pristane-induced lupusM Satoh, J P Weintraub, H Yoshida, et al.
Environmental Health Perspectives|September 30, 1999
Immunopathogenesis of environmentally induced lupus in miceV M Shaheen, M Satoh, H B Richards, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 17, 2013
Secukinumab improves the signs and symptoms of moderate-to-severe plaque psoriasis in subjects with involvement of hands and/or feet: subanalysis of a randomized, double-blind, placebo-controlled, phase 2 dose-ranging studyB Sigurgeirsson, L Kircik, O Nemoto, et al.
The Journal of Clinical Investigation|June 1, 1996
Distinctive immune response patterns of human and murine autoimmune sera to U1 small nuclear ribonucleoprotein C proteinM Satoh, J J Langdon, K J Hamilton, et al.
Arthritis Care & Research|February 25, 2017
Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III StudyH Marzo-Ortega, J Sieper, A Kivitz, et al.
The Journal of Biological Chemistry|November 27, 1999
Autoantibodies define a family of proteins with conserved double-stranded RNA-binding domains as well as DNA binding activityM Satoh, V M Shaheen, P N Kao, et al.
Clinical and Experimental Immunology|August 10, 2000
Widespread susceptibility among inbred mouse strains to the induction of lupus autoantibodies by pristaneM Satoh, H B Richards, V M Shaheen, et al.
The British Journal of Dermatology|October 31, 2012
Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging studyK A Papp, R G Langley, B Sigurgeirsson, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Lupus|October 27, 2001
Titration emulation: a computer-assisted technique that simplifies the quantification of anti-dsDNA antibodies using the Crithidia luciliae assayM Satoh, K M Behney, A Mizutani, et al.
Scandinavian Journal of Rheumatology|February 21, 2018
Secukinumab after anti-tumour necrosis factor-α therapy: a phase III study in active rheumatoid arthritisE Dokoupilová, J Aelion, T Takeuchi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 6, 2000
Fas and Fas ligand mutations inhibit autoantibody production in pristane-induced lupusM Satoh, J P Weintraub, H Yoshida, et al.
Environmental Health Perspectives|September 30, 1999
Immunopathogenesis of environmentally induced lupus in miceV M Shaheen, M Satoh, H B Richards, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 17, 2013
Secukinumab improves the signs and symptoms of moderate-to-severe plaque psoriasis in subjects with involvement of hands and/or feet: subanalysis of a randomized, double-blind, placebo-controlled, phase 2 dose-ranging studyB Sigurgeirsson, L Kircik, O Nemoto, et al.
The Journal of Clinical Investigation|June 1, 1996
Distinctive immune response patterns of human and murine autoimmune sera to U1 small nuclear ribonucleoprotein C proteinM Satoh, J J Langdon, K J Hamilton, et al.
Arthritis Care & Research|February 25, 2017
Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III StudyH Marzo-Ortega, J Sieper, A Kivitz, et al.
The Journal of Biological Chemistry|November 27, 1999
Autoantibodies define a family of proteins with conserved double-stranded RNA-binding domains as well as DNA binding activityM Satoh, V M Shaheen, P N Kao, et al.
Clinical and Experimental Immunology|August 10, 2000
Widespread susceptibility among inbred mouse strains to the induction of lupus autoantibodies by pristaneM Satoh, H B Richards, V M Shaheen, et al.
The British Journal of Dermatology|October 31, 2012
Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging studyK A Papp, R G Langley, B Sigurgeirsson, et al.
Pageof 3